Form 4: Acrivon Therapeutics Executives Exercise Stock Options

Acrivon Therapeutics' President/CEO Peter Blume-Jensen and EVP Kristina Masson report exercising stock options, with vesting schedules extending to February 2035.

Summary

• Peter Blume-Jensen, President and CEO of Acrivon Therapeutics, and Kristina Masson, EVP, reported transactions related to stock options.
• Both executives exercised options to purchase shares of common stock at a price of $5.31 per share on March 1, 2025.
• Blume-Jensen acquired 390,390 shares directly and Masson acquired 140,540 shares indirectly.
• The options vest over time, with 25% vesting on March 1, 2026, and the remainder vesting in 36 equal monthly installments thereafter, contingent upon continuous service.
• The options expire on February 28, 2035.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing. It doesn't inherently convey positive or negative sentiment, simply reporting transactions.

Industry Context

This filing is a routine disclosure of insider transactions, common for publicly traded companies. It provides transparency into the actions of company executives regarding their holdings in the company's stock.

Comparison to Industry Standards

• Stock option grants and exercises are a common form of executive compensation in the biotechnology industry.
• Vesting schedules are typical to incentivize long-term commitment from executives.
• Companies like Amgen, Gilead, and Biogen also utilize stock options as part of their executive compensation packages.

Stakeholder Impact

• The exercise of stock options by executives could have a minor dilutive effect on existing shareholders.
• The vesting schedule incentivizes the executives to remain with the company, which could benefit shareholders.

Key Dates